Christopher B Ward

Address:

2280 Snowfall Ct, Odenton, MD 21113

VIN:

1N4AL21E09N466633

Make:

NISSAN

Model:

ALTIMA

Year:

2009

US Patent:

20120034620, Feb 9, 2012

Filed:

Aug 3, 2011

Appl. No.:

13/196979

Inventors:

Christopher WARD - Baltimore MD, US
William J. LEDERER - Baltimore MD, US
Benjamin L. PROSSER - Baltimore MD, US

Assignee:

UNIVERSITY OF MARYLAND, BALTIMORE - Baltimore MD

International Classification:

G01N 33/53
C12Q 1/02

US Classification:

435 71, 435 29

Abstract:

Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto.

US Patent:

20220273608, Sep 1, 2022

Filed:

May 16, 2022

Appl. No.:

17/745556

Inventors:

Joseph Stains - Laurel MD, US
Christopher Ward - Baltimore MD, US
James Lyons - York PA, US

Assignee:

University of Maryland, Baltimore - Baltimore MD

International Classification:

A61K 31/337
C07K 16/22
A61K 31/165
A61P 19/08
A61K 39/395

Abstract:

Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.

US Patent:

20210214677, Jul 15, 2021

Filed:

Jan 21, 2021

Appl. No.:

17/154239

Inventors:

- Baltimore MD, US
Christopher Ward - Baltimore MD, US
Joseph Stains - Laurel MD, US

International Classification:

C12N 5/00
B01L 3/00
G01N 33/543
C12M 1/32
C12M 1/42

Abstract:

The present invention relates to a fluid flow device. The device includes an elongate body having a proximal end, a distal end, and a length therebetween, at least one source fluid inflow port, at least one waste fluid outflow port, at least one well inlet port positioned at the distal end of the elongate body, at least one well outlet port positioned at the distal end of the elongate body, at least one conduit connecting the at least one source fluid inflow port to the at least one well inlet port, and at least one conduit connecting the at least one waste fluid outflow port to the at least one well outlet port.

US Patent:

20200215035, Jul 9, 2020

Filed:

Jun 19, 2018

Appl. No.:

16/624787

Inventors:

Joseph Pao Yung KAO - Silver Spring MD, US
Christopher William WARD - Baltimore MD, US
Ramzi KHAIRALLAH - New Market MD, US

International Classification:

A61K 31/4184
A61K 31/165
A61K 31/135
A61K 45/06
A61P 21/00

Abstract:

Prodrugs of colchicine, de-acetyl colchicine, colcemid, and nocodazole are provided as therapies for the treatment of diseases ameliorated by the inhibition of microtubule polymerization.

US Patent:

20190351055, Nov 21, 2019

Filed:

Nov 16, 2017

Appl. No.:

16/461555

Inventors:

- Baltimore MD, US
Christopher Ward - Baltimore MD, US
James Lyons - York PA, US

Assignee:

University of Baltimore, Maryland - Baltimore MD

International Classification:

A61K 39/395
A61K 31/337
A61K 31/495
A61K 31/496
A61K 31/365
A61P 19/08

Abstract:

Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject, by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator is further administered to the subject with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator.

US Patent:

20170276666, Sep 28, 2017

Filed:

Mar 22, 2017

Appl. No.:

15/466255

Inventors:

- Baltimore MD, US
Christopher Ward - Baltimore MD, US
Joseph Stains - Laurel MD, US

International Classification:

G01N 33/50
C12N 5/00
B01L 3/00

Abstract:

The present invention relates to a fluid flow device. The device includes an elongate body having a proximal end, a distal end, and a length therebetween, at least one source fluid inflow port, at least one waste fluid outflow port, at least one well inlet port positioned at the distal end of the elongate body, at least one well outlet port positioned at the distal end of the elongate body, at least one conduit connecting the at least one source fluid inflow port to the at least one well inlet port, and at least one conduit connecting the at least one waste fluid outflow port to the at least one well outlet port.

US Patent:

20140256644, Sep 11, 2014

Filed:

May 22, 2014

Appl. No.:

14/284736

Inventors:

Christopher W. Ward - Baltimore MD, US
Ramzi Khairallah - Chicago IL, US

International Classification:

A61K 38/17
A61K 31/12
A61K 31/4178
A61K 31/165

US Classification:

514 174, 514629, 514689, 514381

Abstract:

The present invention provides methods for improving muscular function or treating a muscular disorder in an individual by administering to the individual a pharmacologically effective amount of a compound that inhibits microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production. In addition compounds that block sarcolemmal Ca channel activation and/or renin-angiotensin signaling may be administered with the inhibitor of microtubule-dependent NADPH Oxidase 2 reactive oxygen species signaling production.